WEDNESDAY, Oct. 31 (HealthDay News) -- A firm with the same founders as New England Compounding Center, the pharmacy linked to the deadly meningitis outbreak, announced Wednesday that it would voluntarily recall all of its products.
"Ameridose LLC, based in Westborough, Mass., is voluntarily recalling all of its unexpired products in circulation," the U.S. Food and Drug Administration said in a statement.
"The FDA is currently conducting an inspection of Ameridose's facility," the agency added. "Although this inspection is ongoing, the FDA's preliminary findings have raised concerns about a lack of sterility assurance for products produced at and distributed by this facility."
While the FDA stressed that there have so far been no reports of infections linked to Ameridose products, they say they recommended the recall "out of an abundance of caution."
"Health care professionals and patients may dial the FDA's Drug Information Line at 855-543-DRUG  and press [the star sign] to get the most recent information regarding the Ameridose recall and speak directly to a pharmacist," the agency added.
In the meantime, the death toll from the ongoing fungal meningitis outbreak rose to 29 on Wednesday, with 377 illnesses reported across 19 states.
The newest fatality occurred in Virginia, according to the latest daily tally issued by the U.S. Centers for Disease Control and Prevention.
The recall follows news last week of unsanitary conditions at the Framingham, Mass.-based New England Compounding Center plant. On Friday, federal investigators said their tour of the plant found foreign, "greenish-black" material in some vials of the injectable steroid suspected as the cause of the illnesses.
The contaminated product was one of a host of potential violations discovered during a recent inspection of New England Compounding Center'
All rights reserved